Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash-to-Debt 0.38
HZNP's Cash-to-Debt is ranked lower than
74% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. HZNP: 0.38 )
Ranked among companies with meaningful Cash-to-Debt only.
HZNP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.62 Max: 2.56
Current: 0.38
0.07
2.56
Equity-to-Asset 0.22
HZNP's Equity-to-Asset is ranked lower than
91% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. HZNP: 0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
HZNP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.43 Max: 0.7
Current: 0.22
-0.77
0.7
Debt-to-Equity 2.19
HZNP's Debt-to-Equity is ranked lower than
96% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. HZNP: 2.19 )
Ranked among companies with meaningful Debt-to-Equity only.
HZNP' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.51  Med: 0.67 Max: 2.21
Current: 2.19
-2.51
2.21
Debt-to-EBITDA 21.21
HZNP's Debt-to-EBITDA is ranked lower than
98% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. HZNP: 21.21 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HZNP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -17.45  Med: -0.52 Max: 21.21
Current: 21.21
-17.45
21.21
Piotroski F-Score: 6
Altman Z-Score: 0.34
Beneish M-Score: -3.08
WACC vs ROIC
4.20%
-7.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating Margin % -17.62
HZNP's Operating Margin % is ranked lower than
76% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. HZNP: -17.62 )
Ranked among companies with meaningful Operating Margin % only.
HZNP' s Operating Margin % Range Over the Past 10 Years
Min: -1841.5  Med: -47.53 Max: 7.31
Current: -17.62
-1841.5
7.31
Net Margin % -28.02
HZNP's Net Margin % is ranked lower than
78% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. HZNP: -28.02 )
Ranked among companies with meaningful Net Margin % only.
HZNP' s Net Margin % Range Over the Past 10 Years
Min: -1635.12  Med: -145.04 Max: 5.22
Current: -28.02
-1635.12
5.22
ROE % -31.70
HZNP's ROE % is ranked lower than
79% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. HZNP: -31.70 )
Ranked among companies with meaningful ROE % only.
HZNP' s ROE % Range Over the Past 10 Years
Min: -523.78  Med: -82.51 Max: 4.27
Current: -31.7
-523.78
4.27
ROA % -7.33
HZNP's ROA % is ranked lower than
70% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. HZNP: -7.33 )
Ranked among companies with meaningful ROA % only.
HZNP' s ROA % Range Over the Past 10 Years
Min: -186.55  Med: -49.04 Max: 1.89
Current: -7.33
-186.55
1.89
ROC (Joel Greenblatt) % -923.38
HZNP's ROC (Joel Greenblatt) % is ranked lower than
91% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. HZNP: -923.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HZNP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82  Med: -1847.3 Max: 520.88
Current: -923.38
-7948.82
520.88
3-Year Revenue Growth Rate 22.20
HZNP's 3-Year Revenue Growth Rate is ranked higher than
87% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. HZNP: 22.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HZNP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 22.2 Max: 115.5
Current: 22.2
0
115.5
3-Year EPS without NRI Growth Rate 7.20
HZNP's 3-Year EPS without NRI Growth Rate is ranked lower than
53% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. HZNP: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HZNP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.2 Max: 61.8
Current: 7.2
0
61.8
GuruFocus has detected 4 Warning Signs with Horizon Pharma PLC HZNP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HZNP's 30-Y Financials

Financials (Next Earnings Date: 2018-11-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» HZNP's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades
Q3 2017

HZNP Guru Trades in Q3 2017

Paul Tudor Jones 25,688 sh (New)
Jim Simons 1,109,400 sh (+928.17%)
John Paulson 5,578,850 sh (+13.04%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 2,809,500 sh (-23.10%)
» More
Q4 2017

HZNP Guru Trades in Q4 2017

Paul Tudor Jones 96,558 sh (+275.89%)
Jim Simons 2,279,400 sh (+105.46%)
John Paulson 7,870,700 sh (+41.08%)
Steven Cohen 372,800 sh (-86.73%)
» More
Q1 2018

HZNP Guru Trades in Q1 2018

Steven Cohen 1,312,900 sh (+252.17%)
Jim Simons 3,318,600 sh (+45.59%)
Paul Tudor Jones 137,592 sh (+42.50%)
John Paulson 7,670,700 sh (-2.54%)
» More
Q2 2018

HZNP Guru Trades in Q2 2018

Pioneer Investments 442,300 sh (New)
Jim Simons 5,014,300 sh (+51.10%)
John Paulson 7,670,700 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2018-03-31 Reduce -2.54%0.06%$13.51 - $15.97 $ 18.4125%7,670,700
John Paulson 2017-12-31 Add 41.08%0.65%$13 - $15.07 $ 18.4131%7,870,700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HRTX, NAS:MDCO, SHSE:600216, XLJU:KRKG, HKSE:00460, SZSE:002907, SHSE:600267, SHSE:600277, SHSE:603367, SZSE:002737, SZSE:000078, SHSE:600781, SZSE:300199, TSE:4521, BOM:532296, XKRX:041960, NAS:SUPN, XKRX:145020, XTER:EVT, TSE:4555 » details
Traded in other countries:HPR.Germany,
Headquarter Location:Ireland
Horizon Pharma PLC is a pharmaceutical company. The company focuses on researching, developing and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases.

Horizon Pharma is a specialty and generic drug manufacturing company. The company is focused on the identification, development, acquisition, and commercialization of differentiated and accessible medicines that address unmet medical needs. The overwhelming majority of revenue is generated in the United States. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Horizon Pharma PLC

Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout
June 15, 2018
Read more...
Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontrolled Gout
June 15, 2018
Read more...
Epidemiologic Study Findings Show 27 Percent Increase in Emergency Department Visits for Gout in the United States Over the Past Decade
June 14, 2018
Read more...
Report: Exploring Fundamental Drivers Behind Horizon Pharma Public, Lululemon Athletica, Nordic American Tankers, UBS Group AG, 21Vianet Group, and Sandstorm Gold — New Horizons, Emerging Trends, and Upcoming Developments
June 7, 2018
Read more...
Horizon Pharma plc and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention
June 4, 2018
Read more...
Horizon Pharma plc to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
May 30, 2018
Read more...
Horizon Pharma plc Named One of the Best Small and Medium Workplaces in Chicago by FORTUNE
May 22, 2018
Read more...
Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
May 22, 2018
Read more...
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
May 8, 2018
Read more...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 4, 2018
Read more...

Ratios

vs
industry		 vs
history
Forward PE Ratio 10.99
HZNP's Forward PE Ratio is ranked higher than
77% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. HZNP: 10.99 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.56
HZNP's PB Ratio is ranked lower than
68% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. HZNP: 3.56 )
Ranked among companies with meaningful PB Ratio only.
HZNP' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.28 Max: 14.94
Current: 3.56
0.8
14.94
PS Ratio 2.82
HZNP's PS Ratio is ranked lower than
52% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HZNP: 2.82 )
Ranked among companies with meaningful PS Ratio only.
HZNP' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.79 Max: 19
Current: 2.82
1.47
19
Price-to-Free-Cash-Flow 15.57
HZNP's Price-to-Free-Cash-Flow is ranked higher than
74% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. HZNP: 15.57 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HZNP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.96  Med: 9.96 Max: 433
Current: 15.57
4.96
433
Price-to-Operating-Cash-Flow 14.50
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. HZNP: 14.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HZNP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.84  Med: 9.48 Max: 209.52
Current: 14.5
4.84
209.52
EV-to-EBIT -22.45
HZNP's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. HZNP: -22.45 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -9.1 Max: 219.8
Current: -22.45
-775.4
219.8
EV-to-EBITDA 47.64
HZNP's EV-to-EBITDA is ranked lower than
90% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. HZNP: 47.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -1.1 Max: 518
Current: 47.64
-608
518
EV-to-Revenue 3.95
HZNP's EV-to-Revenue is ranked lower than
59% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. HZNP: 3.95 )
Ranked among companies with meaningful EV-to-Revenue only.
HZNP' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 4.6 Max: 30.2
Current: 3.95
0.5
30.2
Current Ratio 1.70
HZNP's Current Ratio is ranked lower than
65% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. HZNP: 1.70 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.72 Max: 4.39
Current: 1.7
0.16
4.39
Quick Ratio 1.62
HZNP's Quick Ratio is ranked lower than
56% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. HZNP: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.55 Max: 4.27
Current: 1.62
0.16
4.27
Days Inventory 59.90
HZNP's Days Inventory is ranked higher than
81% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. HZNP: 59.90 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 78.91 Max: 201.46
Current: 59.9
13.1
201.46
Days Sales Outstanding 137.37
HZNP's Days Sales Outstanding is ranked lower than
82% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. HZNP: 137.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 96.16 Max: 137.37
Current: 137.37
67.08
137.37
Days Payable 23.02
HZNP's Days Payable is ranked lower than
90% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. HZNP: 23.02 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 23.02  Med: 140.69 Max: 410.36
Current: 23.02
23.02
410.36

Buy Back

vs
industry		 vs
history
3-Year Average Share Buyback Ratio -9.80
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. HZNP: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HZNP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1  Med: -84.9 Max: -9.8
Current: -9.8
-428.1
-9.8

Valuation & Return

vs
industry		 vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.22
HZNP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. HZNP: 1.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HZNP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.89 Max: 29.51
Current: 1.22
0.94
29.51
Price-to-Median-PS-Value 0.74
HZNP's Price-to-Median-PS-Value is ranked higher than
59% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. HZNP: 0.74 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HZNP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.03 Max: 4.48
Current: 0.74
0.46
4.48
Earnings Yield (Greenblatt) % -4.46
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. HZNP: -4.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HZNP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -913.1  Med: -4.8 Max: 2.6
Current: -4.46
-913.1
2.6

More Statistics

Revenue (TTM) (Mil) $1,072.58
EPS (TTM) $ -1.83
Beta0.46
Volatility32.55%
52-Week Range $12.55 - 21.25
Shares Outstanding (Mil)166.63

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 1.41 1.75
EPS without NRI ($) 1.41 1.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontr Jun 15 2018 
Horizon Pharma plc Presents Data at EULAR 2018 Advancing the Understanding and Management of Uncontr Jun 15 2018 
Epidemiologic Study Findings Show 27 Percent Increase in Emergency Department Visits for Gout in th Jun 14 2018 
Report: Exploring Fundamental Drivers Behind Horizon Pharma Public, Lululemon Athletica, Nordic Amer Jun 07 2018 
Horizon Pharma plc and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Pr Jun 04 2018 
Thinking about buying stock in Apple, American Eagle Outfitters, Horizon Pharma, Micron or Verastem? May 31 2018 
Horizon Pharma plc to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference May 30 2018 
Horizon Pharma plc Named One of the Best Small and Medium Workplaces in Chicago by FORTUNE May 22 2018 
Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living w May 22 2018 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of May 08 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}